European Huntington's Disease Network
 | This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (March 2022) (Learn how and when to remove this template message) |
| Abbreviation | EHDN |
|---|---|
| Formation | 2003 |
| Type | International Network |
| Legal status | Constitution |
| Purpose | The EHDN aims to advance knowledge of Huntington’s disease by promoting and supporting research efforts to develop and test therapeutic interventions that will improve the quality of life of people with Huntington’s disease (see https://www.euro-hd.net/html/network/project/constitution/article1). |
| Headquarters | Ulm, Germany |
Region served | Europe |
Official language | English (and others) |
Chair | Professor Anne Rosser |
| Affiliations |
|
| Website | ehdn.org |
The European Huntington's Disease Network (EHDN)[1] is an independent nonprofit network dedicated to advancing research, conducting clinical trials and improving care for people affected by Huntington’s disease (HD). It was founded in 2003 by Professor G. Bernhard Landwehrmeyer who chaired the Executive Committee until 2014. Through the EHDN, a platform has been created such that basic scientists, clinicians, patients and families can collaborate on academic and industry studies to fulfil its stated mission.[2] The EHDN is supported by and collaborates closely with CHDI Foundation, Inc.
As of December 2021, EHDN had over 2,800 regular members and over 400 associate members representing European and further countries worldwide. EHDN's activities and strategy are governed by the Executive Committee and Central Coordination forms the core of all operational activities. Language Area Coordinators are the bridge between the EHDN and its clinical sites throughout Europe.[3] The EHDN Think Tank[4] complements and facilitates EHDN research initiatives, in part through liaison with the EHDN Working Groups and Task Forces.[5] Finally, the Scientific and Bioethics Advisory Committee[6] is responsible for reviewing research projects submitted to the EHDN that require access to data and biosamples or funding under the EHDN seed fund scheme.[7]
References[edit]
- ↑ "European Huntington's Disease Network – Advancing Research, Conducting Trials, Improving Care". www.ehdn.org. Retrieved 2022-03-08.
- ↑ "About EHDN – European Huntington's Disease Network". www.ehdn.org. Retrieved 2022-03-08.
- ↑ "EHDN Structure – European Huntington's Disease Network". www.ehdn.org. Retrieved 2022-03-08.
- ↑ "EHDN Think Tank – European Huntington's Disease Network". www.ehdn.org. Retrieved 2022-03-08.
- ↑ "EHDN Working Groups and Task Forces – European Huntington's Disease Network". www.ehdn.org. Retrieved 2022-03-08.
- ↑ "EHDN Structure – European Huntington's Disease Network". www.ehdn.org. Retrieved 2022-03-08.
- ↑ "Seed Fund Applications – European Huntington's Disease Network". www.ehdn.org. Retrieved 2022-03-08.
External links[edit]
.jpeg){kind=small} | This article about a scientific organization is a stub. You can help EverybodyWiki by expanding it. |
This article "European Huntington's Disease Network" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:European Huntington's Disease Network. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
